Bayer (BAYN) Given a €125.00 Price Target by Jefferies Group Analysts
Bayer (FRA:BAYN) has been given a €125.00 ($148.81) price target by investment analysts at Jefferies Group in a report issued on Tuesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Jefferies Group’s target price would suggest a potential upside of 19.55% from the stock’s current price.
A number of other equities research analysts also recently commented on the company. UBS Group set a €125.00 ($148.81) price objective on Bayer and gave the company a “buy” rating in a report on Thursday, December 7th. Barclays set a €100.00 ($119.05) price target on Bayer and gave the stock a “sell” rating in a report on Tuesday, December 12th. Commerzbank set a €124.00 ($147.62) price target on Bayer and gave the stock a “buy” rating in a report on Wednesday, November 15th. Nord/LB set a €102.00 ($121.43) price target on Bayer and gave the stock a “neutral” rating in a report on Friday, December 8th. Finally, Berenberg Bank set a €124.00 ($147.62) price target on Bayer and gave the stock a “neutral” rating in a report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company’s stock. Bayer has a consensus rating of “Buy” and a consensus price target of €121.76 ($144.95).
Shares of Bayer (BAYN) opened at €104.56 ($124.48) on Tuesday. The company has a market capitalization of $86,400.00 and a PE ratio of 28.03. Bayer has a fifty-two week low of €99.69 ($118.68) and a fifty-two week high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.